Waldenstrom Macroglobulinemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Waldenstrom macroglobulinemia markets reached a value of US$ 152.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 234.2 Million by 2034, exhibiting a growth rate (CAGR) of 4% during 2024-2034.
The Waldenstrom macroglobulinemia market has been comprehensively analyzed in IMARC's new report titled "Waldenstrom Macroglobulinemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Waldenstrom macroglobulinemia refers to a rare form of cancer that belongs to a group of disorders known as lymphoproliferative neoplasms. It is characterized by the overproduction of a specific type of abnormal white blood cell called lymphoplasmacytic cells, which accumulate in the bone marrow and produce monoclonal immunoglobulin M (IgM) protein. The most common symptoms associated with the illness include fatigue, weakness, enlarged lymph nodes and spleen, anemia, bleeding problems, easy bruising, nosebleeds, etc. Individuals suffering from this ailment may also experience indications related to high levels of IgM, such as thickened blood or hyperviscosity. The diagnosis of Waldenstrom macroglobulinemia involves several steps, including medical history evaluation, physical examination, laboratory tests, and imaging studies. A bone marrow biopsy is also crucial to detect characteristic findings and confirm the presence of abnormal lymphocytes in patients. The healthcare provider may further perform numerous other diagnostic procedures and tests, like a complete blood count, a computed tomography scan, serum protein electrophoresis, etc., to validate the underlying cause as well as evaluate the extent and spread of the disease.
The increasing cases of inherited disorders resulting from genetic mutations, which cause uncontrolled growth and accumulation of lymphoplasmacytic cells, are primarily driving the Waldenstrom macroglobulinemia market. In addition to this, the growing geriatric population, who are susceptible to various physiological changes and impaired immune system functioning, is creating a positive outlook for the market. Moreover, the widespread adoption of chemotherapy regimens, including bendamustine, cyclophosphamide, fludarabine, etc., to alleviate disease symptoms by reducing the proliferation of cancerous cells and decreasing the production of abnormal proteins is further bolstering the market growth. Apart from this, the escalating application of plasmapheresis procedures, since they help to lower the concentration of IgM, thereby enhancing blood flow and preventing complications related to high serum viscosity, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of interferon-alpha therapy to treat the disorder owing to its several associated benefits, such as stimulating the immune system, inhibiting cell growth, and improving disease control, is expected to drive the Waldenstrom macroglobulinemia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Waldenstrom macroglobulinemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Waldenstrom macroglobulinemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Waldenstrom macroglobulinemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Waldenstrom macroglobulinemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Waldenstrom macroglobulinemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Waldenstrom macroglobulinemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Waldenstrom macroglobulinemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Waldenstrom macroglobulinemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Waldenstrom macroglobulinemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Waldenstrom macroglobulinemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of Waldenstrom macroglobulinemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Waldenstrom macroglobulinemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Waldenstrom macroglobulinemia across the seven major markets?
What is the size of the Waldenstrom macroglobulinemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Waldenstrom macroglobulinemia?
What will be the growth rate of patients across the seven major markets?
Waldenstrom Macroglobulinemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Waldenstrom macroglobulinemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Waldenstrom macroglobulinemia market?
What are the key regulatory events related to the Waldenstrom macroglobulinemia market?
What is the structure of clinical trial landscape by status related to the Waldenstrom macroglobulinemia market?
What is the structure of clinical trial landscape by phase related to the Waldenstrom macroglobulinemia market?
What is the structure of clinical trial landscape by route of administration related to the Waldenstrom macroglobulinemia market?
The Waldenstrom macroglobulinemia market has been comprehensively analyzed in IMARC's new report titled "Waldenstrom Macroglobulinemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Waldenstrom macroglobulinemia refers to a rare form of cancer that belongs to a group of disorders known as lymphoproliferative neoplasms. It is characterized by the overproduction of a specific type of abnormal white blood cell called lymphoplasmacytic cells, which accumulate in the bone marrow and produce monoclonal immunoglobulin M (IgM) protein. The most common symptoms associated with the illness include fatigue, weakness, enlarged lymph nodes and spleen, anemia, bleeding problems, easy bruising, nosebleeds, etc. Individuals suffering from this ailment may also experience indications related to high levels of IgM, such as thickened blood or hyperviscosity. The diagnosis of Waldenstrom macroglobulinemia involves several steps, including medical history evaluation, physical examination, laboratory tests, and imaging studies. A bone marrow biopsy is also crucial to detect characteristic findings and confirm the presence of abnormal lymphocytes in patients. The healthcare provider may further perform numerous other diagnostic procedures and tests, like a complete blood count, a computed tomography scan, serum protein electrophoresis, etc., to validate the underlying cause as well as evaluate the extent and spread of the disease.
The increasing cases of inherited disorders resulting from genetic mutations, which cause uncontrolled growth and accumulation of lymphoplasmacytic cells, are primarily driving the Waldenstrom macroglobulinemia market. In addition to this, the growing geriatric population, who are susceptible to various physiological changes and impaired immune system functioning, is creating a positive outlook for the market. Moreover, the widespread adoption of chemotherapy regimens, including bendamustine, cyclophosphamide, fludarabine, etc., to alleviate disease symptoms by reducing the proliferation of cancerous cells and decreasing the production of abnormal proteins is further bolstering the market growth. Apart from this, the escalating application of plasmapheresis procedures, since they help to lower the concentration of IgM, thereby enhancing blood flow and preventing complications related to high serum viscosity, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of interferon-alpha therapy to treat the disorder owing to its several associated benefits, such as stimulating the immune system, inhibiting cell growth, and improving disease control, is expected to drive the Waldenstrom macroglobulinemia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Waldenstrom macroglobulinemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Waldenstrom macroglobulinemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Waldenstrom macroglobulinemia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Waldenstrom macroglobulinemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Waldenstrom macroglobulinemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Waldenstrom macroglobulinemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Waldenstrom macroglobulinemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Waldenstrom macroglobulinemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Waldenstrom macroglobulinemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Waldenstrom macroglobulinemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of Waldenstrom macroglobulinemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Waldenstrom macroglobulinemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Waldenstrom macroglobulinemia across the seven major markets?
What is the size of the Waldenstrom macroglobulinemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Waldenstrom macroglobulinemia?
What will be the growth rate of patients across the seven major markets?
Waldenstrom Macroglobulinemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Waldenstrom macroglobulinemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Waldenstrom macroglobulinemia market?
What are the key regulatory events related to the Waldenstrom macroglobulinemia market?
What is the structure of clinical trial landscape by status related to the Waldenstrom macroglobulinemia market?
What is the structure of clinical trial landscape by phase related to the Waldenstrom macroglobulinemia market?
What is the structure of clinical trial landscape by route of administration related to the Waldenstrom macroglobulinemia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 WALDENSTROM MACROGLOBULINEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 WALDENSTROM MACROGLOBULINEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 WALDENSTROM MACROGLOBULINEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 WALDENSTROM MACROGLOBULINEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 WALDENSTROM MACROGLOBULINEMIA - UNMET NEEDS
10 WALDENSTROM MACROGLOBULINEMIA - KEY ENDPOINTS OF TREATMENT
11 WALDENSTROM MACROGLOBULINEMIA - MARKETED PRODUCTS
11.1 List of Waldenstrom Macroglobulinemia Marketed Drugs Across the Top 7 Markets
11.1.1 Brukinsa (Zanubrutinib) - BeiGene
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Imbruvica (Ibrutinib) - Janssen/Pharmacyclics
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 WALDENSTROM MACROGLOBULINEMIA - PIPELINE DRUGS
12.1 List of Waldenstrom Macroglobulinemia Pipeline Drugs Across the Top 7 Markets
12.1.1 Ulocuplumab - Bristol-Myers Squibb
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 APG2575 - Ascentage Pharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Acalabrutinib - Acerta Pharma/AstraZeneca
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Pirtobrutinib - Eli Lilly and Company
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Daratumumab - Janssen Biotech
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. WALDENSTROM MACROGLOBULINEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. WALDENSTROM MACROGLOBULINEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 WALDENSTROM MACROGLOBULINEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Waldenstrom Macroglobulinemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Waldenstrom Macroglobulinemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Waldenstrom Macroglobulinemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Waldenstrom Macroglobulinemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Waldenstrom Macroglobulinemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Waldenstrom Macroglobulinemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Waldenstrom Macroglobulinemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Waldenstrom Macroglobulinemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
16 WALDENSTROM MACROGLOBULINEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 WALDENSTROM MACROGLOBULINEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 WALDENSTROM MACROGLOBULINEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 WALDENSTROM MACROGLOBULINEMIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 WALDENSTROM MACROGLOBULINEMIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 WALDENSTROM MACROGLOBULINEMIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 WALDENSTROM MACROGLOBULINEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 WALDENSTROM MACROGLOBULINEMIA - UNMET NEEDS
10 WALDENSTROM MACROGLOBULINEMIA - KEY ENDPOINTS OF TREATMENT
11 WALDENSTROM MACROGLOBULINEMIA - MARKETED PRODUCTS
11.1 List of Waldenstrom Macroglobulinemia Marketed Drugs Across the Top 7 Markets
11.1.1 Brukinsa (Zanubrutinib) - BeiGene
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Imbruvica (Ibrutinib) - Janssen/Pharmacyclics
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 WALDENSTROM MACROGLOBULINEMIA - PIPELINE DRUGS
12.1 List of Waldenstrom Macroglobulinemia Pipeline Drugs Across the Top 7 Markets
12.1.1 Ulocuplumab - Bristol-Myers Squibb
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 APG2575 - Ascentage Pharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Acalabrutinib - Acerta Pharma/AstraZeneca
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Pirtobrutinib - Eli Lilly and Company
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Daratumumab - Janssen Biotech
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. WALDENSTROM MACROGLOBULINEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. WALDENSTROM MACROGLOBULINEMIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 WALDENSTROM MACROGLOBULINEMIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Waldenstrom Macroglobulinemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Waldenstrom Macroglobulinemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Waldenstrom Macroglobulinemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Waldenstrom Macroglobulinemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Waldenstrom Macroglobulinemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Waldenstrom Macroglobulinemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Waldenstrom Macroglobulinemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Waldenstrom Macroglobulinemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
16 WALDENSTROM MACROGLOBULINEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 WALDENSTROM MACROGLOBULINEMIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 WALDENSTROM MACROGLOBULINEMIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
